Publication date: Jul 11, 2023
Background: There are limited clinical data comparing extended dosing (ED) versus standard dosing (SD) of pembrolizumab for metastatic non-small-cell lung cancer. Methods: This retrospective study included patients with metastatic non-small-cell lung cancer and PD-L1 tumor proportion score ≥50% treated with one or more cycles of single-agent pembrolizumab with SD or ED from January 2018 to December 2020. Results: A higher proportion of patients were alive in the ED group (vs SD) at 6 months (94 vs 51%), 12 months (94 vs 33%) and data cutoff (94 vs 26%) (p
| Concepts | Keywords |
|---|---|
| 6months | alternative dosing |
| Cancer | immunotherapy |
| December | non-small-cell lung cancer |
| Pandemic | outcomes |
| Pembrolizumab | pembrolizumab |
| safety |
Semantics
| Type | Source | Name |
|---|---|---|
| drug | DRUGBANK | Pembrolizumab |
| disease | IDO | cell |
| disease | MESH | lung cancer |
| disease | MESH | COVID-19 pandemic |
| disease | MESH | tumor |
Original Article
(Visited 1 times, 1 visits today)